• OPEN AN ACCOUNT
Indian Indices
Sensex
83,371.98 -198.37
( -0.24%)
Global Indices
Nasdaq
49,379.59 -83.86
(-0.17%)
Dow Jones
6,960.70 -4.77
(-0.07%)
Hang Seng
53,565.61 -370.56
(-0.69%)
Nikkei 225
10,219.48 -19.46
(-0.19%)
Forex
USD-INR
90.32 0.07
(0.08%)
EUR-INR
104.98 -0.13
(-0.12%)
GBP-INR
121.10 -0.20
(-0.16%)
JPY-INR
0.57 0.00
(0.21%)

EQUITY - MARKET SCREENER

Newgen Software Technologies Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
540900
INE619B01017
103.6012798
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NEWGEN
34.35
10663.16
EPS(TTM)
Face Value()
Div & Yield %
21.81
10
0.66
 

Alembic Pharma receives USFDA approval for Diltiazem hydrochloride tablets
Nov 15,2025

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.